Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 11/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937036 | 1.00 | HTR1B (0.56) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL16902842 | 0.87 | HTR1B (0.64) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL11057929 | 0.84 | KCNA3 (0.54) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL667918 | 0.82 | HTR1B (0.65) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL30007810 | 0.82 | HTR1B (0.65) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL23499970 | 0.81 | KCNA3 (0.54) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL30186241 | 0.81 | KCNA3 (0.54) | HTR1BHTR1DSLC6A4HRH1KDM4E | |
| SCHEMBL10984843 | 0.81 | KCNA3 (0.69) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL29820187 | 0.81 | MAPT (0.63) | KDM4EALDH1A1HPGDKCNA3TDP1 | |
| SCHEMBL1446528 | 0.81 | MAPT (0.63) | KDM4EALDH1A1HPGDKCNA3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4121411-A1 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| EP-4065583-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021188728-A1 | SELECTIVE NON-CYCLIC NUCLEOTIDE ACTIVATORS FOR THE CAMP SENSOR EPAC1 | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021107160-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021106231-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-03 | — | — | WO | disclosed |
| CN-111992196-A | (R) -BIONL derivative CSP filler and preparation method and application thereof | 昆明医科大学 | 2020-11-27 | — | — | CN | disclosed |
| CN-109843856-A | KRAS G12C inhibitor | 米拉蒂治疗股份有限公司 | 2019-06-04 | — | — | CN | disclosed |
| EP-0376288-B1 | Naphthalene derivative | EISAI CO LTD (JP) | 1994-03-09 | — | — | EP | disclosed |
| US-5134111-A | Inhibitors of interleukin-1 as antiinflammatory agents | EISAI CO., LTD. (JP) | 1992-07-28 | — | — | US | disclosed |
| EP-0201071-B1 | 2-SUBSTITUTED-1-NAPHTHOLS AS 5-LIPOXYGENASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-03-04 | — | — | EP | disclosed |
| US-5026759-A | Antiinflammatory agents respiratory system disorders | DU PONT MERCK PHARMACEUTICAL (US) | 1991-06-25 | — | — | US | disclosed |
| US-4985442-A | ANTIINFLAMMATORY, LUNG DISEASES, PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| US-4985435-A | TREATMENT OF INFLAMMATION, OBSTRUCTIVE LUNG DISEASES AND PSORIASIS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-01-15 | — | — | US | disclosed |
| EP-0376288-A1 | Naphthalene derivative | Eisai Co., Ltd. (JP) | 1990-07-04 | — | — | EP | disclosed |
| US-4906636-A | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1990-03-06 | — | — | US | disclosed |
| US-4833164-A | ANTIINFLAMMATORY AGENTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-05-23 | — | — | US | disclosed |
| EP-0201071-A2 | 2-Substituted-1-naphthols as 5-lipoxygenase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1986-11-12 | — | — | EP | disclosed |